Wells Fargo Starts Ares Commercial (ACRE) at Outperform; Strong Company Within mREIT Sector
Get Alerts ACRE Hot Sheet
Price: $4.62 -2.12%
Rating Summary:
5 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
5 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Wells Fargo initiates coverage on Ares Commercial (NYSE: ACRE) with an Outperform. PT range $19-21.
Analyst, Joel Houck, said, "Our rating is based on (1) ACRE’s strong and seasoned management team along with its affiliation with Ares Management, (2) ACRE’s platform advantage through a direct middle market focused origination platform, (3) ACRE’s flexible financing solutions entailing a variety of structures not readily available in today’s environment for middle market commercial real estate borrowers. We are establishing 2012 and 2013 EPS estimates of $0.76 and $1.89, respectively."
For an analyst ratings summary and ratings history on Ares Commercial click here. For more ratings news on Ares Commercial click here.
Shares of Ares Commercial closed at $16.76 yesterday.
Analyst, Joel Houck, said, "Our rating is based on (1) ACRE’s strong and seasoned management team along with its affiliation with Ares Management, (2) ACRE’s platform advantage through a direct middle market focused origination platform, (3) ACRE’s flexible financing solutions entailing a variety of structures not readily available in today’s environment for middle market commercial real estate borrowers. We are establishing 2012 and 2013 EPS estimates of $0.76 and $1.89, respectively."
For an analyst ratings summary and ratings history on Ares Commercial click here. For more ratings news on Ares Commercial click here.
Shares of Ares Commercial closed at $16.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Starts Huntington Bancshares (HBAN) at Overweight
- Needham Starts Pulse Biosciences (PLSE) at Buy
- BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share